Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
GeneDx Holdings Corp. - Class A Common Stock
(NQ:
WGS
)
19.61
-0.78 (-3.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about GeneDx Holdings Corp. - Class A Common Stock
< Previous
1
2
Next >
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
May 04, 2023
New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
May 03, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Reverse Stock Split
April 28, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
April 18, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel
April 03, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
March 20, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
March 16, 2023
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic odyssey
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 14, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
March 01, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
February 28, 2023
Research illustrates company’s progress in working to end the diagnostic odyssey and includes data with implications for how care is delivered to patients beginning at birth
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
February 21, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases
February 16, 2023
Research published in Nature Genetics underscores the role of genetic insights in the drug discovery and development process
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering
January 31, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery
January 30, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering
January 27, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering
January 26, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.